In another cancer model, we have shown that bemcentinib abrogates autophagic flux in erlotinib-resistant lung cancer HCC827 cells, in association with increased cell surface expression of MHC I molecules, and markers of immunogenic cell death (ICD) revealed by the release of ATP, in addition to two other damage-associated molecular patterns (DAMPs); release of High Mobility Group Box 1 (HMGB1) and cell surface-exposed calreticulin (126) (Figure 4). Here, HMGB1 is linked to cancer.